Twist1 and Twist2 are major regulators of embryogenesis. Twist1 has been shown to favor the metastatic dissemination of cancer cells through its ability to induce an epithelial-mesenchymal transition (EMT). Here, we show that a large fraction of human cancers overexpress Twist1 and/or Twist2. Both proteins override oncogene-induced premature senescence by abrogating key regulators of the p53-and Rb-dependent pathways. Twist1 and Twist2 cooperate with Ras to transform mouse embryonic fibroblasts. Interestingly, in epithelial cells, the oncogenic cooperation between Twist proteins and activated mitogenic oncoproteins, such as Ras or ErbB2, leads to complete EMT. These findings suggest an unanticipated direct link between early escape from failsafe programs and the acquisition of invasive features by cancer cells.
INTRODUCTION
Twist proteins are highly conserved basic helix-loop-helix (bHLH) transcription factors that have important regulatory functions during embryogenesis. In Drosophila, the ancestral Twist protein (named DTwist) is crucial for proper gastrulation and mesoderm formation (Simpson, 1983; Thisse et al., 1987) . In mammals, two Twist-like proteins, Twist1 and Twist2, share high structural homology (Li et al., 1995; Wolf et al., 1991) . Gene deletion experiments have shown that TWIST1 is required for closure of the neural tube during mouse development (Chen and Behringer, 1995) , while TWIST2 knockout mice display elevated expression of proinflammatory cytokines causing perinatal death (Sosic et al., 2003) . Interestingly, this phenotype is also found in individuals doubly heterozygous for TWIST1 and TWIST2 alleles, reflecting some functional redundancy (Bialek et al., 2004) . While Twist proteins are only expressed in a subset of mesodermally and ectodermally derived tissues, TWIST1 is overexpressed in various human solid tumors including numerous types of carcinomas as well as sarcomas, gliomas, neuroblastomas, and melanomas Kwok et al., 2005; Mironchik et al., 2005; Zhang et al., 2007; Ohuchida et al., 2007; Entz-Werle et al., 2005; Elias et al., 2005; ValsesiaWittmann et al., 2004; Hoek et al., 2004) . The role of Twist1 in tumor progression has been convincingly associated with the metastatic process . Exogenous overexpression
SIGNIFICANCE
Because cells are frequently subjected to abnormal growth signals, multicellular organisms develop two major safeguard programs, senescence and apoptosis, that can eliminate potentially deleterious cells at early stages of tumor development. The mechanisms by which precancer cells escape these protective barriers remain to be determined. Herein, we identify Twist proteins as decisive early drivers of tumorigenesis. Indeed, Twist1 and Twist2 abrogated oncogene-induced senescence by inhibiting key regulators of this safeguard program. Strikingly, this deleterious effect was associated with complete epithelial-mesenchymal transition (EMT), a process associated with the acquisition of invasive potential. These observations suggest that some metastatic capabilities of cancer cells can be acquired during malignant conversion as a side effect of the inactivation of primary failsafe mechanisms.
of Twist1 increases the invasive and metastatic abilities of human cancer cells by promoting the downregulation of E-cadherin and the induction of an epithelial-mesenchymal transition (EMT) Kwok et al., 2005; Mironchik et al., 2005) . EMT, which was first recognized as a feature of embryogenesis, converts epithelial cells into mesenchymal cells and promotes cell motility through profound disruption of cell-cell junctions and extensive reorganization of the actin cytoskeleton (Hay, 1995) .
The results presented herein indicate that TWIST2, similarly to TWIST1, is overexpressed in a large variety of human primary tumors and cancer cell lines. We next demonstrate that both Twist1 and Twist2 inhibit premature senescence in cancer cells, a process identified as an initial barrier to tumor development. Indeed, senescence occurs in vivo in precancerous lesions in response to aberrant mitogenic signaling, and its inactivation is required for progression toward malignancy (Chen et al., 2005; Michaloglou et al., 2005; Collado et al., 2005) . We further show that this property allows Twist proteins to cooperate with mitogenic oncoproteins, resulting in full transformation of murine cells. Interestingly, in human epithelial cells, escape from premature senescence mediated by Twist1 or Twist2 is associated with complete EMT. Altogether, these findings suggest an as yet undescribed link between early escape from failsafe programs and acquisition of metastatic features.
RESULTS

Twist1 and Twist2
Override Oncogene-Induced Senescence in Murine and Human Cancer Cells Twist1 has been shown to play a major role in breast cancer progression by promoting EMT and favoring the metastatic process . To further evaluate the role of both Twist proteins in carcinoma progression, we first took advantage of the MMTV-ErbB2/Neu transgenic mouse model (unactivated rat ErbB2/Neu gene under the transcriptional control of the mouse mammary tumor virus promoter/enhancer). ERBB2 is a major oncogene involved in human breast tumorigenesis, and this mouse model is considered to be an appropriate tool for deciphering the molecular pathways involved in breast cancer progression. After a long latency, which is believed to represent the time required for mammary epithelial cells to acquire additional cooperative events, MMTV-ErbB2/Neu transgenic mice stochastically develop focal mammary tumors that can eventually metastasize to the lungs (Guy et al., 1992) . Analysis of TWIST1 and TWIST2 expression in twenty independent spontaneous mammary tumors demonstrated a frequent activation of the TWIST2 gene (Figure 1 ). Indeed, whereas TWIST1 expression levels remained weak in all tumors, TWIST2 was significantly upregulated (p < 0.0001) in 12 of them (60%), suggesting that Twist2 might be involved in tumor progression.
In an initial approach to define potential Twist2 oncogenic functions, cancer cell lines derived from either TWIST2-positive or -negative tumors from MMTV-ErbB2/Neu transgenic mice were established, and the consequences of TWIST2 depletion by RNA interference were evaluated. Surprisingly, knockdown of TWIST2 in TWIST2-expressing cell lines invariably triggered cellular senescence characterized by flattened cytoplasm, G1 growth arrest, senescence-associated b-galactosidase (SA-b-gal) activity, and induction of the de novo marker of cellular senescence DEC1 (Qian et al., 2008; Collado et al., 2005) (Figure 2 ). Similar results were obtained using two independent TWIST2 shRNA sequences. As expected, these two shRNAs had no effect on TWIST2-negative cell lines, thus demonstrating the specificity of the observation.
As aberrant activation of ErbB2 in mammary epithelial cells triggers a premature senescence response (Trost et al., 2005) , our observations suggested that Twist2 induction might override oncogene-induced senescence in vivo. This property was not limited to murine cells. In fact, TWIST2 but also TWIST1 depletion promoted senescence in human melanoma and breast cancer cell lines (Figure 3) , linking Twist1 and Twist2 to the inactivation of this failsafe program.
TWIST1 and TWIST2 Are Frequently Overexpressed in Human Cancers Whereas the overexpression of TWIST1 has already been described in a large variety of tumors, the status of TWIST2 in malignancies remains largely unknown. We thus measured TWIST1 and TWIST2 mRNA levels in a wide range of human tumors (n = 148) and human tumor-derived cell lines (n = 64) encompassing eight different cancer types ( Figure 4A ; see also Figure S1 available online). Overall, TWIST1 and TWIST2 were significantly upregulated in primary tumor cells (p = 0.002 and p = 0.04, respectively) and in cancer cell lines (p < 0.0001 and p = 0.0042, respectively) compared to their normal counterparts. As shown in Figure 4A , TWIST1 and TWIST2 overexpression was particularly frequent in melanoma samples. Melanomas are malignant proliferation of cutaneous melanocytes that can develop from benign nevi. Premature senescence is a major safeguard mechanism preventing the progression from nevi to melanomas (Michaloglou et al., 2005 Figure 4B ).
Twist1 and Twist2 Cooperate with Activated Ras for Malignant Transformation and Disrupt Both p53 and Rb Tumor Suppressor Pathways
The induction of premature senescence following constitutive activation of the Ras/Raf mitogenic pathway is particularly well documented (Serrano et al., 1997) .
To further study the biological effects of Twist1 and Twist2, standard cooperation assays were performed in primary murine embryonic fibroblasts (MEFs) using an activated form of H-Ras (H-Ras V12 ).
As expected, MEFs infected only with H-Ras V12 immediately stopped growing and underwent senescence characterized by flattened cytoplasm, induction of SA-b-gal activity, and G1 growth arrest (data not shown). In contrast, cells sequentially infected with H-Ras V12 and either Twist1 or Twist2 continued proliferating ( Figure 5A ) and could be maintained in culture for months. MEFs overexpressing both H-Ras V12 and Twist1 or Twist2 exhibited hallmarks of malignant Figure S2 ). Although the time required for tumor growth varied slightly, clonogenic and tumorigenic capabilities were observed even in the presence of relatively low levels of ectopic Ras and/or Twist expression (data not shown). Upon histological examination, expanding xenografts displayed all of the features of aggressive sarcomas, with high levels of aberrant mitosis, anisokaryosis, and major angiogenic activity, further demonstrating a potent oncogenic cooperation between Twist proteins and Ras ( Figure 5 ). Of note, although Twist proteins have been shown to regulate proinflammatory cytokine gene expression (Sosic et al., 2003) , microarray analysis of MEFs and transformed MEFs did not show striking differences in expression of chemokines, interleukins, and their receptors (Table S1 ).
The p53 and Rb tumor suppressor pathways are known to play a pivotal role in the onset of premature senescence (Serrano et al., 1996) . To further investigate the mechanisms by which Twist proteins inhibit oncogene-induced failsafe programs, we compared the endogenous expression of p16 Ink4a , ARF, p53, and p21 Cip1 in MEFs infected with H-Ras V12 alone or in combination with Twist1 or Twist2 retroviral expression constructs. As shown in Figure 6A , Twist1 or Twist2 expression was sufficient to completely abrogate p16
Ink4a and p21 Cip1 induction by activated Ras without downregulating ARF and p53 levels. Identical inhibitory effects were observed in cell lines either generated through the MEF transformation assays (Ras + Twist1, Ras + Twist2) or derived from tumors induced in athymic nude mice ( Figure 6A ). To confirm that Twist per se was sufficient to abrogate p16
Ink4A and p21 Cip1 activation, we knocked down TWIST1 expression using RNA interference in Ras + Twist1-transformed MEFs. As shown in Figure 6B , inhibition of TWIST1 expression led to a significant reinduction of the expression of both cyclin-dependent kinase inhibitors. Nevertheless, this reinduction was not sufficient to trigger senescence, which might be due to residual ectopic Twist1. and p53 ( Figures 6C and 6D ). Although the molecular mechanisms involved in this effect are still under investigation, preliminary experiments suggest that the ability of Twist proteins to prevent the Ras-mediated activation of p16 INK4A might be associated with their ability to interact with the Ras effector Ets2 ( Figure S3 ).
Twist1 and Twist2 Overcome Premature Senescence and Cooperate Further with Mitogenic Oncoproteins to Promote EMT and Invasiveness
The ability of Twist1 and Twist2 to overcome oncogene-induced senescence was confirmed in a variety of human cells including primary mammary epithelial cells (HMECs) (Figure 7 ), IMR90 and MRC5 diploid fibroblasts ( Figure S4 ), and immortalized BJ primary fibroblasts expressing an inducible version of H-Ras V12 (data not shown). In all cases, expression of Twist1 or Twist2 completely abolished premature senescence induced by the activated mitogenic oncoprotein. We thereby confirmed that Twist1 or Twist2 overexpression was sufficient to override this crucial primary safeguard mechanism, thus providing a rationale for the observed oncogenic cooperation. Intriguingly, experiments with HMECs revealed a second level of cooperation. As shown in earlier studies , ectopic expression of Twist1 alone in HMECs triggered several features of EMT (Figure 7) . However, Twist1-mediated EMT was only partial as demonstrated by the observed cellular morphology, the significant but incomplete decrease of the E-cadherin epithelial marker, and the modest increase of the vimentin mesenchymal marker ( Figures 7A and 7B ). Of note, a similar effect was also observed with Twist2. In contrast, expression of both Twist1 (or Twist2) and H-Ras V12 (or ErbB2) triggered a total loss of E-cadherin, an increase in vimentin expression (Figure 7 and data not shown), and a concomitant acquisition of invasive properties ( Figure 7C) . A cooperative effect between Twist and mitogenic oncoproteins on the acquisition of mesenchymal features and invasive properties was also observed in Ras-transformed mammary epithelial MCF10A cells (MCF10A cells retrovirally infected by Ras V12 , MCF10A pLX Ras V12 ) ( Figure S5 ) (Konishi et al., 2007) .
Because the role of Twist1 in the induction of EMT was originally demonstrated in polarized Madin-Darby canine kidney (MDCK) epithelial cells , we next examined the effects of Twist1 or Twist2 in the presence or absence of H-Ras V12 in these cells. In line with previous observations, overexpression of Twist1 or Twist2 alone was sufficient to trigger some morphological features of EMT, including a fibroblastic morphology, associated with a significant decrease of epithelial markers and increase of mesenchymal protein levels. Nevertheless, as demonstrated by the additional reduction of epithelial markers and further increase of mesenchymal protein expression, complete EMT required the presence of H-Ras V12 , confirming the cooperative effect (Figure 8 ). The mechanisms underlying this observation remain unknown. EMT is regulated by an elaborate interplay of signaling pathways. However, it is noteworthy that oncogenic Ras has been shown to cooperate with TGF-b to induce EMT (Oft et al., 1996) and that TGF-b is believed to act through the induction of several transcription repressors, including Twist1 (Kang and Massague, 2004) . Taken together, our results highlight an unexpected doublebarreled oncogenic cooperation between Twist proteins and mitogenic oncoproteins such as Ras and ErbB2. On one hand, Twist1 or Twist2 allows cancer cells to override premature senescence, and on the other hand, concomitant activation of Twist and mitogenic signaling promotes complete EMT, thereby facilitating invasion and metastasis.
DISCUSSION
Aberrant cell proliferation and malignant transformation induced by some oncogenes are restrained by cellular senescence (Serrano et al., 1997) . First considered as a cell culture artifact, premature senescence was recently confirmed in vivo as an early barrier against tumor progression (Bartkova et al., 2005; Chen et al., 2005; Gorgoulis et al., 2005; Collado et al., 2005) . Indeed, it occurs in many different precancerous tissues in both humans and mice but is absent in malignant tumors, suggesting that its inactivation is a general requirement for full-blown cancer progression. However, the mechanisms allowing premalignant cells to bypass this primary failsafe program remain The role of Twist proteins in the inhibition of premature senescence is concordant with previous studies that reported the induction of Twist1 expression during the progression toward malignant stages in several cancer types including prostate, bladder, and pancreatic lesions (Kwok et al., 2005; Zhang et al., 2007; Ohuchida et al., 2007) . The inverse correlation between p16
Ink4a and Twist1 protein levels in nevi and melanoma samples also supports the role of Twist proteins as negative modulators of p16 INK4A and as crucial inhibitors of oncogeneinduced senescence in human cancer cells. As we have previously demonstrated that Twist1 and Twist2 are able to inhibit Myc-induced apoptosis in vitro and in vivo (Maestro et al., 1999; Valsesia-Wittmann et al., 2004) , Twist proteins appear to act as general inhibitors of oncogene-induced safeguard programs. Noticeably, in response to activated Ras, Twist1 and Twist2 appear to act by downregulating the cyclin-dependent kinase inhibitors p16 Ink4a and p21 Cip1 without affecting ARF levels, whereas ARF is a crucial Twist target in response to aberrant Myc activation (Maestro et al., 1999; Valsesia-Wittmann et al., 2004) . Although the underlying mechanisms remain to be determined, the differential effect on ARF gene expression has been confirmed in reporter assays (data not shown).
Escape from oncogene-induced senescence and apoptosis being a general prerequisite for malignant conversion, our observations suggest that Twist1 and Twist2 are early drivers of tumor progression and provide a rationale for the high frequency of TWIST1 and TWIST2 overexpression in a large variety of human tumors. Furthermore, these findings shed new light on the role of Twist proteins in EMT and metastasis. Several groups have previously reported that high Twist1 expression promotes EMT and correlates with tumor invasion and metastasis in a variety of human cancers Mironchik et al., 2005; Kang and Massague, 2004) . Overall, our data show that in cells with aberrant mitogenic signaling, Twist1 or Twist2 reactivation overrides primary safeguard mechanisms to trigger cell transformation and, as a side effect, promotes EMT in cooperation with mitogenic oncoproteins, favoring invasiveness. In conditions where the mitogenic activation does not trigger senescence (due either to low levels of oncoprotein or to alternative mechanisms leading to a deregulation of safeguard programs), Twist1 and Twist2 do not display major transforming capabilities but still cooperate with activated oncoproteins in promoting EMT ( Figures S5  and S6 ).
A prevailing model proposes that transcription factors involved in EMT promotion, such as Twist1, Snail, and Slug, are induced in rare cancer cells residing at the invasive edge of advanced carcinomas in response to signals released by the activated stroma (Scheel et al., 2007) . According to this model, TWIST1 induction will not provide any growth advantage within the primary tumor and will specifically favor cell dissemination, particularly the steps of motility and invasiveness. Based on our observations, we propose an alternative model in which, in the presence of aberrant mitogenic signaling, reactivation of the developmental proteins Twist1 and Twist2 promotes the transition from a premalignant to a malignant stage by inactivation of innate failsafe programs. Due to the cooperative effect of Twist1 or Twist2 and mitogenic factors on EMT promotion, this model predicts that most of the cancer cells within the primary tumor will be responsive to EMT-inducing signals from the microenvironment, highly increasing the risk of metastatic dissemination.
Challenging the classical view of metastasis as the final step of tumor progression, recent observations further support the notion that early transformed cells are capable of dissemination. Specifically, Klein and colleagues have reported that disseminated cancer cells in the bone marrow of breast cancer patients exhibit different and fewer alterations than their matched primary tumors (Schmidt-Kittler et al., 2003; Schardt et al., 2005) . By using BALB/c mice transgenic for the activated rat ErbB2/Neu gene, the same group recently demonstrated that dissemination of epithelial cells begins shortly after expression of the oncogenic transgene, as early as the stage of atypical hyperplastic lesion (Husemann et al., 2008) . Strikingly, unlike both normal mammary glands and the invasion front of advanced tumors, these early lesions are characterized by a significant overexpression of TWIST1 (of note, TWIST2 expression was not examined by these authors). Although further work is warranted to confirm these observations in human cancers, these and our findings support the hypothesis that reactivation of Twist proteins in vivo promotes malignant conversion concomitantly with metastatic dissemination.
EXPERIMENTAL PROCEDURES
Constructs N-terminally FLAG-tagged human Twist1, Twist2, and H-Ras V12 proteins were expressed from the pBabe, pCI-neo, or pcDNA3 expression vectors (Promega). The human ERBB2 cDNA was subcloned into the pBabe retroviral expression vector. Human ARF, p16
INK4A
, and p21 CIP1 luciferase reporter constructs have been described previously (Linggi et al., 2002; Hara et al., 1996; el-Deiry et al., 1993) . The H-Ras V12 pBabe and the Bmi-1 pBabe expression constructs were generous gifts from the laboratories of Robert A. Weinberg and Goberdhan P. Dimri. shRNAs directed against the human TWIST1 gene (shRNA hTWIST1 A, 5 0 -GCTGAGCAAGATTCAGACC-3 0 Cell Culture and Retroviral Infection Primary MEFs (derived from C57BL/6 3 DBA2 F1 mice), E1A-immortalized MEFs, transformed MEF cell lines, and tumor-derived cell lines were maintained in DMEM supplemented with 10% fetal bovine serum, 1% penicillin/ streptomycin, 1 mM HEPES (GIBCO), and 0.1 mM nonessential amino acids. RPMI 7951, T47D, MDCK, MCF10A, and HMEC cell lines were grown as recommended by the American Type Culture Collection (ATCC).
Plt-E and Plt-A producer cells were used to generate retroviral stocks. 3 3 10 6 Plt-E (-A) cells were transfected by calcium phosphate precipitation with 10 mg of retroviral vector and then placed after 24 hr in 5 ml of fresh medium for viral production. Forty-eight hours after transfection, the supernatant was collected, filtered (0.45 mm, Millipore), and supplemented with 4 mg/ml of polybrene (Sigma). The viral stock was placed in contact with 1 3 10 6 MEFs (or 2.5 3 10 5 human cells) for 3 hr, and infected cells were selected after 24 hr with appropriate antibiotics. Cooperation assays were performed by sequential infections using Ras-or ErbB2-expressing constructs and Twist1, Twist2, or empty (pBabe) expression constructs, spaced by a 48 hr period of time.
Foci formation and growth on agar were assessed as described in Petrenko et al. (2003) . TWIST1 and/or TWIST2 depletion experiments were performed by a double 48 hr-spaced infection of cells with retroviral or lentiviral shRNA expression virus using Plt-E or 293T cells as packaging cell lines. Reporter Assays 3 3 10 5 E1A-immortalized MEFs were cotransfected with 1.5 mg of reporter construct, 0.5 mg of expression vector, and 0.3 mg of internal pRL-TK-luc construct (Promega) using jetPEI transfectant (Q-Biogen). Twenty-four hours after transfection, luciferase activity was monitored using the Dual-Luciferase Reporter Assay System (Promega) and a luminometer (Luminoskan Ascent, Labsystem).
Real-Time qRT-PCR
Mouse Xenografts
Animal maintenance and experiments were carried out in accordance with the animal care guidelines of the European Union and with French laws and were validated by the Comité Ré gional d'Ethique Animale CNRS Rhô ne-Alpes. Sixweek-old female athymic Swiss nude mice (Charles River Laboratories) were subcutaneously grafted in the left flank with 1 3 10 5 Ras + Twist1 or Twist2 retrovirally infected MEFs. Tumor growth was monitored twice a week with calipers at the site of injection. Animals were allowed to form tumors up to 1.5 cm in diameter, at which point they were euthanized. Each tumor was dissected and either fixed in formaldehyde and processed for histopathologic examination or used for protein or RNA extraction.
Immunoblot Analysis
Cell lysates were prepared in RIPA buffer. Protein expression was examined by western blotting using rabbit anti-mouse p16 Ink4a M-156 and anti-human Characterization of Senescent Cells SA-b-Galactosidase Staining Cells were fixed in 3% formaldehyde, washed three times with PBS, and incubated at 37 C for 12 hr in buffer containing 40 mM sodium phosphate (pH 6), 5 mM K 4 Fe(CN) 6 , 5 mM K 3 Fe(CN) 6 , 150 mM NaCl, 2 mM MgCl 2 , and 1 mg/ml X-Gal.
Flow Cytometry Analysis
Trypsinized cells were washed in PBS, fixed in cold 70% ethanol/PBS for 30 min, washed, and incubated for 1 hr in 1 ml PBS containing 0.1 mg/ml RNase A and 20 mg/ml propidium iodide. Cell-cycle profiles were then determined using a FACSCalibur flow cytometer (BD Biosciences), and data were analyzed using CellQuest software.
Immunofluorescence Analysis Cells were seeded onto glass coverslips 24 hr prior to treatments. Cells were fixed with 4% formaldehyde for 10 min, permeabilized with 0.1% Triton X-100 for 20 min at room temperature, saturated for 30 min with 10% FCS in PBS, washed in PBS, incubated overnight at 4 C with monoclonal anti-E-cadherin (BD Biosciences) or anti-vimentin V9 (Dako) antibodies, and then incubated for 1 hr with FITC-or TRITC-conjugated rabbit anti-mouse antibodies (Dako). Cells were counterstained with 2 mg/ml Hoechst (33258, Sigma). Coverslips were then mounted with Fluoromount-G (Southern Biotech).
Immunohistochemistry
Routine formalin-fixed and paraffin-embedded excision biopsies of a series of melanocytic neoplasms (including 12 nevi and 10 melanomas) were analyzed. Immunohistochemistry was performed on 5 mm tissue sections. All specimens were immunostained with a non-biotin detection system (Bond Polymer Refine, Leica Microsystems), with diaminobenzidine development. Heat-induced antigen retrieval was performed using Tris-EDTA buffer (pH 9.0) in a water bath at 95 C for 30 min. Monoclonal anti-p16 Ink4a (clone JC8, NeoMarkers) and antiTwist1 (clone Twist2C1a, Biomatrix) antibodies were used. Stainings were performed with an automatic immunostainer (Bond System, Leica Microsystems).
Matrigel Invasion Assays
Matrigel (BD Biosciences) was added to the wells of an eight-well Labtek chamber in a volume of 300 ml/well. A Matrigel plug of about 1 mm diameter was removed. The hole was successively filed with 1 3 10 5 cells and 100 ml of Matrigel. Appropriate growth medium was added on top. Cultures were analyzed for up to 4 days. Areas of migration were visualized using an Olympus IX50 (NA 0.075). Samples were performed in duplicate.
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